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Abstract 
Background: iRhom2 is an inactive rhomboid protease involved in diverse signalling events. It has 
been implicated in the pathogenesis of a number of cancer types, including oesophageal and ovarian 
cancer, while its closely associated family member, iRhom1, is implicated in head and neck cancer. 
However, a role for iRhom2 in head and neck cancer has not been investigated.  
Methods & Results: Immunoblotting for iRhom2 in 54 oral squamous cell carcinoma (OSCC) and 
24 paired normal tissues demonstrated higher levels of iRhom2 protein in tumour compared with 
normal samples (P<0.05). iRhom2 over-expression correlated with poor patient survival (P<0.0005) 
but with no other clinicopathological variable. Increased cell migration was observed in stably over-
expressing iRhom2 clones of OSCC cell lines in the absence of increased cell proliferation, but not 
in  the normal oral keratinocyte cell line, NOK-hTERT, and this was abrogated by knock-down of 
iRhom2.  
Conclusions: iRhom2 protein expression is increased in a proportion of OSCC and this up-
regulation is associated with faster cell migration and decreased patient survival. These data 
implicate iRhom2-controlled signalling events in the pathogenesis of this cancer. 
  
3 
 
1 Introduction 
Rhomboids are intramembrane serine proteases, with their active and catalytic residues located 
within the cell membrane lipid bilayer, enabling them to easily cleave and activate / inactivate 
membrane proteins within their transmembrane helices [1]. Although lacking protease function, 
iRhom2 has been shown to be involved in diverse signalling events such as the trafficking/activation 
of important growth and signalling factors, e.g. ADAM17, EGFR, and TGFα  [2,3]. iRhom2 has 
been implicated in the pathogenesis of a number of cancer types including oesophageal and ovarian 
cancer [4], while its closely associated family member, iRhom1, is implicated in EGFR signalling 
in head and neck cancer [5], but evidence for a specific role for iRhom2 in head and neck squamous 
cell carcinoma (HNSCC) has not been described. 
HNSCC was reported to be the eighth most common cancer type in the UK in 2014. Worldwide, it 
is the sixth leading cancer type by incidence, with more than 550,000 cases and about 300,000 
deaths in 2014 [6].  The 5 year overall survival in this cancer remains at approx. 50% [7] despite 
advances in surgical and chemoradiation treatments, implicating hitherto unexplored pathways.. 
This investigation focuses on the possible oncogenic role of  iRhom2 in oral squamous cell 
carcinomas, the most common form of HNSCC, and its possible utility as a biomarker for survival.  
2 Materials & methods 
2.1 Patients 
Fresh, frozen tissues were obtained from 54 OSCC tumours and 24 paired normal adjacent 
tissues. Written consent was obtained from all patients (REC numbers: EC.47.01 & 10/H1002/53). 
The tissues were snap frozen at point of surgery and stored at -80ᴼC prior to use. Demographic and 
clinicopathological data was collected. 
Frozen tissues were embedded in OCT and a 5μm section assessed for tumour presence. 
Tumour samples with less than 60% tumour content were excluded. Normal samples with more than 
5% tumour content were also excluded.  
2.2 Cell lines and cell culture 
The oral cancer cell lines, PE/CA-PJ15 [8] (source: ECACC) and Liv37K, a locally derived, 
low passage cell line, both showed detectable levels of iRhom2 expression and were selected to 
represent an established oral cancer cell model and a ‘close to the tumour’ oral cancer cell model, 
respectively. The normal oral keratinocyte cell line, NOK-hTERT [9] (Source: Prof Karl Münger,  
The Channing Laboratory, Brigham and Womens Hosptial, Boston, USA) was selected as a control. 
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All cell lines were cultured at 37℃ in 5.0% carbon dioxide. Liv37K was used at or below passage 
10 for all experiments reported here. 
Cell monolayers were scraped into 10ml PBS, followed by centrifugation to recover cell pellets 
which were stored at -80ᴼC prior to protein extraction. The identity of the cell lines was confirmed 
by STR typing using GenePrint10® (Promega) and were mycoplasma negative by E-Myco PCR 
detection kit (CHEMBIO Ltd). 
2.3 Protein extraction 
5mm³ pieces of tissue were excised from areas with an increased number of tumour cells or 
lack of tumour as appropriate (determined from H&E sections) and re-suspended in protein 
extraction buffer (50 mM Tris–HCl, pH 6.8, 1% SDS, 1% EDTA, 0.25% glycerol, 0.25% β-
mercaptoethanol with protease inhibitor (Roche Diagnostics), and sonicated for 30 seconds to 
extract total protein which was stored at -80ᵒC until use. Recovered cell pellets were re-suspended 
in protein extraction buffer and similarly processed.   
2.4 Western blot analysis 
Protein samples were loaded unto 10% SDS/PAGE gels. TE3-RHBDF2, an oesophageal cancer 
cell line constitutively expressing iRhom2, was used as a positive control. Following 
electrophoresis, gels were transferred to 0.45μm PVDF membranes (GE Healthcare Life Sciences) 
and western blotting carried out. Membranes were blocked for one hour in PBS/Licor Blocking 
Buffer, ratio 1:1 then probed, using rabbit polyclonal anti-RHBDF2 (1:500: Sigma Aldrich: 
HPA018080) or mouse monoclonal anti-β-actin (1:1000: SantaCruz: sc-4778) at room temperature 
for 2 hours. Fluorescently labelled secondary antibodies; IRDye@800 goat anti-rabbit  (Licor) and 
Alexa Flour@680 rabbit anti-mouse (Life Technologies), were used at a concentration of 1: 10,000. 
Visualisation of fluorescent secondary antibody localisation was undertaken on a Licor Odyssey 3.0 
imager (Licor Biosciences UK Ltd). 
Densitometry was used to normalise and semi-quantitate the levels of protein expression in 
comparison with the actin control and the positive control sample run on each gel. Samples were 
ascribed a status of high (or overexpression) or moderate (or normal expression) based on a cut-off 
of 19.9 relative absorbance units, which was determined to be the boundary of the 75th percentile 
from the cumulative frequency curve of the expressing samples. Samples demonstrating no 
measurable expression were classified as no expression. 
2.5 Stable transfection 
Clones of PE/CA-PJ15, Liv37K and NOK-hTERT that stably over-expressed RHBDF2 were 
created by transfection with a 5.3kb pIRESneo vector (Clontech) containing isoform 2 of RHBDF2 
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(Epoch Life Science Inc). shRNA knock-down of RHBDF2 gene was achieved using 
Mission®shRNA (SIGMA – 09051604MN) with Mission®pLKO.1-puro B2M shRNA control 
(SIGMA-SHC008-04021321MN)( Sigma-Aldrich/Merck). 
2.6 Proliferation assay 
A crystal violet assay was used to assess proliferation. Briefly, cells were seeded into 6 well 
plates and harvested daily for 5 days, then stained with 0.05% crystal violet solubilised in 10% 
acetic acid and absorbance read at 570nm using a Spectramax-Plus284 absorbance microplate reader 
(Molecular Devices) against a 10% acetic acid blank.  
2.7 Migration assay 
Cells were seeded in triplicate into removable chambers (Ibidi, Thistle Scientific) placed in 6 
well plates, then cultured until they reached approximately 85% confluency. The removable inserts 
were withdrawn and the plates transferred to culture chamber attached to a Nikon Eclipse TE300 
microscope for image capture at ten minutes intervals for 30 hours. Gap closure images were 
analysed on Image J (https://imagej.nih.gov/ij/) and T-Scratch [10]. 
2.8 Statistical Analysis 
Protein expression data from tissue was analysed using box plot analysis and paired sample t 
test (SPSS statistics, version 24). Chi-squared and the Kaplan-Meier survival tests were used to 
analyse associations between tissue expression and clinicopathological features.  
3 Results  
3.1 Expression of iRhom2 in OSCC and normal oral tissues 
iRhom2 protein was highly expressed in 19/54 (35%) tumour samples, moderately expressed 
in 17/54 (31%) tumour samples, and undetected in the remaining 18/54 (33%) (Figure 1,Table 1). 
In contrast, iRhom2 protein was highly expressed in only 1/24 (4%) normal samples, moderately 
expressed in 5/24 (21%) normal samples and undetectable in the remaining 18/24 (75%) (P<0.05).  
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Fig. 1 Representative western blot of iRhom2 expression in normal and tumour tissue. N: normal 
tissue; T: tumour tissue; TE3 +ve: cell line overexpressing iRhom2 (+ve control for normalisation 
between gels) 
 
Table 1: Distribution of levels of iRhom2 protein expression in oral squamous cell tumour and 
adjacent normal tissue determined by western blotting  
iRhom2 protein expression a Tumour tissue 
(n=54) 
Normal tissue 
(n=24) 
High  
(>19.9 arbitrary densitometry units) 
19 (35%) 1 (4%) 
Moderate (>0 and <19.9 units) 17 (31%) 5 (21%) 
Absent 18 (33%) 18 (75%) 
a: high and moderate expression were defined as the boundary of the 75th percentile and obtained 
from the cumulative frequency of all expressing samples (see materials and methods)  
 
No significant correlations were observed between iRhom2 protein expression in tumours and 
their clinicopathological features, except that high levels of iRhom2 expression were shown to 
correlate negatively with overall survival (P<0.0005) (Figure 2). 
7 
 
 
Fig. 2 Kaplan-Meier analysis of overall survival in relation to levels of iRhom2 protein expression 
determined on western blots. Overexpression (green line) and normal expression (blue line) were 
defined  using cumulative frequency (see materials and methods). Censored data (i.e. living patients 
whose follow-up period is less than 120 months) is represented as a vertical bar on the relevant line. 
Four samples had missing survival data 
 
3.2 Impact of altered expression of iRhom2 in cell lines 
In contrast to data in the literature, the rate of proliferation was not increased in any of the cell 
lines by overexpression of iRhom2  (Supplementary Figures 1 & 2), but was reduced in Liv37K 
and, to a lesser degree, in NOK-hTERT, while having no apparent effect on PE/CA-PJ15.  
Despite the lack of increase in cell proliferation, PE/CA-PJ15 and Liv37K clones with up-
regulated iRhom2 migrated approximately twice as fast as their respective wild-type variants 
(Figures 3A,B,C,D), with the knockdown clone of PE/CA-PJ15 showing a slower rate of migration 
than the wild type variant (Figure 3A,B). Neither iRhom2 over-expression nor shRNA knock-down 
appeared to alter the rate of migration of NOK-hTERT cells (Figure 3E,F).  
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Fig. 3 2D migration of oral cell lines. A, C, E: Freeze frame photography at the time points indicated. 
B, D, F: graphical representations of the rates of wound closure showing the amount of scratch remaining 
unclosed at the time points indicated. A & B: PE/CA-PJ15 cell line variants; C & D: Liv37K variants; 
E & F: NOK-hTERT variants. Black line with squares : wild type (WT); grey line with triangles: 
overexpressing clone; pale line with circles: shRNA knockdown clone 
 
4 Discussion  
A role for iRhom2 has been proposed in oesophageal and ovarian cancer [4], but evidence for 
a specific role in HNSCC has not been described. We have now shown that iRhom2 protein 
expression is often upregulated in OSCC in comparison to adjacent normal tissues (P<0.05). 
Furthermore, increased iRhom2 expression correlated with poor survival (P<0.0005), but did not 
correlate with any other clinicopathological indicators of prognosis, such as extracapsular spread or 
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tumour size, suggesting that it may be an independent prognostic indicator. However, the sample 
size was too small to assess this statistically.  
iRhom2 has been shown to be involved in diverse signalling events such as the 
trafficking/activation of important growth and signalling factors, e.g. ADAM17, EGFR, and TGFα 
(transforming growth factor α) [2,3]. ADAM17, also known as TACE (Tumour Necrosis Factor-α 
converting enzyme), is involved in the shedding of signalling molecules such as TNFα, TGFα, EGF, 
Notch1 and CD44, and adhesion molecules such as L-selectin, syndecans, CAMs (Cell Adhesion 
Molecules) and cadherins [11-13]. Following its synthesis, ADAM17 protein is thought to be largely 
stored in the ER in immature form, prior to maturation in the Golgi apparatus and onward trafficking 
to the cell membrane [14]. Therefore, only a fraction of the mature / activated form is demonstrated 
to be available at the cell membrane at any one time [14] and trafficking to the cell membrane is 
thought to be orchestrated by iRhom2 [2]. Increased ADAM17 expression has been shown to lead 
to poor survival in OSCC orthotopic animal models [15] and may thus be implicated as the 
downstream initiator of iRhom2. 
To augment our observational study on clinical samples, we both over-expressed and knocked 
down iRhom2 expression in two oral cancer cell lines and one immortalised normal oral 
keratinocyte cell line. Interestingly, cell proliferation was not shown to be augmented by increased 
expression  of iRhom2 and these date are in contrast to the literature that suggests a proliferative 
role for iRhom2 [16,17]. Upregulation of iRhom2 in the two cancer cell lines increased their rate of 
2D migration in a wound healing assay but did not confer a similar advantage to a non-cancerous 
oral epithelial cell line. This data again implicates ADAM17 as the effector as this has been 
associated with poor prognosis and promotion of  oral cancer cell line migration via inactivating 
cleavage of CXCL1, a cell adhesion regulator [18]. Furthermore, motility of cancer associated 
fibroblasts in culture has been shown to be dependent on iRhom2-dependent, ADAM17-mediated 
cleavage of TGF beta receptor 1 [19].  
These data implicate activation of the iRhom2-ADAM17 pathway in the pathogenesis of 
OSCC, and suggest that this system works by influencing or increasing rate of cell migration. 
Deregulation of ADAM17 has previously been implicated in head and neck squamous cell 
carcinoma (HNSCC) [20], with up-regulation of ADAM17, as well as increased sheddase activity, 
correlating with tumour aggressiveness, rate of growth and prognosis in this and other cancers [20-
-23]. Increased ADAM17 sheddase activity has also been demonstrated following increased 
expression of the protein in head and neck cancer cell lines [20]. Although the exact mechanism 
remains largely unclear, there is some evidence to suggest that upregulated ADAM17 in head and 
neck cancer plays key roles in tumour initiation and progression via proteolytic and/or adhesive 
properties [20]. This may relate in turn to our data indicating poor survival in those patients whose 
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cancers overexpressed iRhom2.  However, additional research is required to completely unravel the 
signalling pathways involved and confirm whether modulation of iRhom2 expression may be a 
future target for therapy or useful as a prognostic marker.  
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Supplementary Fig. 1 Overexpression and shRNA knockdown of iRhom2 isoform 2 in oral cell 
lines. Western blot (A, B, C), and protein quantification (D, E, F) of iRhom2 using densitometry 
(arbitrary units). A & D: PE/CA-PJ15; B & E: Liv37K; C & F: NOK-hTERT. WT: wild type; Over: 
overexpressing clone; shRNA: shRNA knockdown of the overexpressing clone; scrambled: shRNA 
control. Arrows on western blots indicate the expected position of iRhom2 isoform 2 and beta actin.  
Negative control contains no protein and is not analysed in the quantification charts.  
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Supplementary Fig. 2 Crystal violet proliferation assay. Viable cell population, represented by the 
absorbance, is plotted against time in days. Black line with squares: wild type (WT); grey line with 
triangles: overexpressing clone; pale line with circles: shRNA knockdown clone. It was not possible 
to obtain a Liv37K knockdown for comparison, despite using 2 shRNA molecules separately and in 
combination 
 
 
